Free Trial

STERIS (STE) Competitors

$222.88
-0.34 (-0.15%)
(As of 05/31/2024 ET)

STE vs. BDX, EW, DXCM, IDXX, RMD, BAX, HOLX, PODD, TFX, and GMED

Should you be buying STERIS stock or one of its competitors? The main competitors of STERIS include Becton, Dickinson and Company (BDX), Edwards Lifesciences (EW), DexCom (DXCM), IDEXX Laboratories (IDXX), ResMed (RMD), Baxter International (BAX), Hologic (HOLX), Insulet (PODD), Teleflex (TFX), and Globus Medical (GMED). These companies are all part of the "health care equipment" industry.

STERIS vs.

Becton, Dickinson and Company (NYSE:BDX) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, institutional ownership, risk, community ranking, media sentiment and dividends.

87.0% of Becton, Dickinson and Company shares are held by institutional investors. Comparatively, 94.7% of STERIS shares are held by institutional investors. 0.3% of Becton, Dickinson and Company shares are held by insiders. Comparatively, 1.0% of STERIS shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Becton, Dickinson and Company received 266 more outperform votes than STERIS when rated by MarketBeat users. Likewise, 62.33% of users gave Becton, Dickinson and Company an outperform vote while only 58.41% of users gave STERIS an outperform vote.

CompanyUnderperformOutperform
Becton, Dickinson and CompanyOutperform Votes
589
62.33%
Underperform Votes
356
37.67%
STERISOutperform Votes
323
58.41%
Underperform Votes
230
41.59%

In the previous week, Becton, Dickinson and Company and Becton, Dickinson and Company both had 17 articles in the media. STERIS's average media sentiment score of 0.48 beat Becton, Dickinson and Company's score of 0.11 indicating that Becton, Dickinson and Company is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Becton, Dickinson and Company
8 Very Positive mention(s)
2 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
STERIS
5 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
2 Negative mention(s)
0 Very Negative mention(s)
Neutral

Becton, Dickinson and Company pays an annual dividend of $3.80 per share and has a dividend yield of 1.6%. STERIS pays an annual dividend of $2.08 per share and has a dividend yield of 0.9%. Becton, Dickinson and Company pays out 83.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. STERIS pays out 54.5% of its earnings in the form of a dividend. Becton, Dickinson and Company has increased its dividend for 52 consecutive years and STERIS has increased its dividend for 19 consecutive years. Becton, Dickinson and Company is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Becton, Dickinson and Company has a beta of 0.45, suggesting that its share price is 55% less volatile than the S&P 500. Comparatively, STERIS has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Becton, Dickinson and Company currently has a consensus price target of $280.17, suggesting a potential upside of 20.78%. STERIS has a consensus price target of $241.60, suggesting a potential upside of 8.40%. Given STERIS's stronger consensus rating and higher probable upside, analysts clearly believe Becton, Dickinson and Company is more favorable than STERIS.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Becton, Dickinson and Company
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
STERIS
0 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.50

STERIS has a net margin of 6.95% compared to STERIS's net margin of 6.76%. STERIS's return on equity of 13.90% beat Becton, Dickinson and Company's return on equity.

Company Net Margins Return on Equity Return on Assets
Becton, Dickinson and Company6.76% 13.90% 6.73%
STERIS 6.95%13.73%7.74%

Becton, Dickinson and Company has higher revenue and earnings than STERIS. Becton, Dickinson and Company is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Becton, Dickinson and Company$19.37B3.46$1.48B$4.5451.09
STERIS$5.14B4.29$378.24M$3.8258.35

Summary

Becton, Dickinson and Company beats STERIS on 12 of the 20 factors compared between the two stocks.

Get STERIS News Delivered to You Automatically

Sign up to receive the latest news and ratings for STE and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding STE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

STE vs. The Competition

MetricSTERISSurgical appliances & supplies IndustryMedical SectorNYSE Exchange
Market Cap$22.04B$8.98B$5.17B$17.88B
Dividend Yield0.93%1.28%2.76%3.50%
P/E Ratio58.3513.75110.1222.61
Price / Sales4.2951.632,386.0710.18
Price / Cash15.8820.5935.4119.14
Price / Book3.494.285.545.90
Net Income$378.24M$182.64M$106.07M$976.46M
7 Day Performance-2.74%-1.26%1.14%0.62%
1 Month Performance8.05%-1.96%0.65%3.61%
1 Year Performance8.47%-12.44%2.69%20.81%

STERIS Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
BDX
Becton, Dickinson and Company
4.8905 of 5 stars
$226.78
+0.8%
$280.17
+23.5%
-6.5%$65.54B$19.37B49.9573,000Analyst Forecast
Short Interest ↓
EW
Edwards Lifesciences
4.7507 of 5 stars
$87.89
+1.0%
$95.06
+8.2%
+2.0%$52.96B$6.00B37.8819,800Analyst Forecast
Insider Selling
Short Interest ↓
DXCM
DexCom
4.9599 of 5 stars
$118.40
-7.2%
$141.67
+19.7%
-0.7%$47.09B$3.62B76.399,600Analyst Forecast
Short Interest ↓
High Trading Volume
IDXX
IDEXX Laboratories
4.3526 of 5 stars
$499.77
+0.3%
$580.38
+16.1%
+5.8%$41.28B$3.66B48.3811,000Positive News
RMD
ResMed
4.6109 of 5 stars
$209.35
+1.6%
$202.80
-3.1%
-5.7%$30.76B$4.22B32.1610,140Analyst Revision
Positive News
BAX
Baxter International
4.9436 of 5 stars
$33.44
+0.8%
$44.42
+32.8%
-17.3%$17.04B$14.81B6.4360,000Analyst Forecast
Short Interest ↓
HOLX
Hologic
4.8455 of 5 stars
$72.58
+0.3%
$85.60
+17.9%
-6.8%$16.94B$4.03B37.036,990
PODD
Insulet
4.915 of 5 stars
$175.95
+2.1%
$239.18
+35.9%
-35.0%$12.32B$1.70B53.323,000Analyst Forecast
Insider Selling
Short Interest ↑
Positive News
TFX
Teleflex
4.4277 of 5 stars
$206.64
+2.0%
$257.29
+24.5%
-10.6%$9.73B$2.97B33.1714,500Short Interest ↑
Analyst Revision
High Trading Volume
GMED
Globus Medical
4.7417 of 5 stars
$66.59
+2.0%
$69.40
+4.2%
+22.0%$9.01B$1.57B104.045,000Analyst Forecast
Short Interest ↓
Analyst Revision
News Coverage
Positive News

Related Companies and Tools

This page (NYSE:STE) was last updated on 6/2/2024 by MarketBeat.com Staff

From Our Partners